Literature DB >> 16940716

Cardiac vascular calcification and QT interval in ESRD patients: is there a link?

Biagio R Di Iorio1, Sara Bortone, Carmine Piscopo, Pellegrino Grimaldi, Emanuele Cucciniello, Ernesto D'Avanzo, Fiorentino Mondillo, Nicola Cillo, Vincenzo Bellizzi.   

Abstract

We will present our experience and our preliminary data about the correlation between cardiac calcification and QT interval (and QT dispersion) in uraemia. We studied 32 haemodialysis (HD) patients (age 69 +/- 16 years, time on dialysis 32 +/- 27 months) and 12 chronic kidney disease stage 4 (CKD-4) patients (age 66 +/- 17 years, uraemia duration 38 +/- 16 months). The patients were characterized by a good mineral control, as shown by serum phosphate levels (3.6 +/- 1.3 mg/dl in CKD-4 and 4.3 +/- 1.6 mg/dl in HD patients) and Ca x P product (46 +/- 17 and 49 +/- 16 mg(2)/dl(2), respectively). The parathyroid hormone levels were higher in HD than CKD-4 patients (p < 0.0001). A TC score >400 was found to be highly prevalent in both groups. Significantly more HD patients (62.5%) showed cardiac calcification than CKD-4 patients (33%; p = 0.01). The patients were matched for TC scores higher or lower than 400. The two groups differed by gender (p < 0.05), age (p = 0.026), frequency of diabetes mellitus (p < 0.01), uraemia follow-up period (p < 0.001), low-density lipoprotein cholesterol level (p = 0.009), Ca x P product (p = 0.002), parathyroid hormone level (p < 0.0001), and corrected QT dispersion (p < 0.0001). The QT interval was higher in HD and CKD-4 patients with higher TC scores (approximately 11%), but QT interval dispersion was significantly higher in patients with TC scores >400. QT dispersion showed a linear correlation with TC scores in both groups (r = 0.899 and p < 0.0001 and r = 0.901 and p < 0.0001). Male gender, age, time (months) of uraemia, low-density lipoprotein cholesterol, albumin, calcium x phosphorus product, parathyroid hormone, and TC score are important determinants of QT dispersion. Our data show that it is possible to link dysrhythmias and cardiac calcification in uraemic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940716     DOI: 10.1159/000095362

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

1.  QT dispersion predicts mortality and correlates with both coronary artery calcification and atherosclerosis in hemodialysis patients.

Authors:  Murat Guney; Abdullah Ozkok; Yasar Caliskan; Hamdi Pusuroglu; Halil Yazici; Savas Tepe; Huseyin Oflaz; Alaattin Yildiz
Journal:  Int Urol Nephrol       Date:  2013-09-14       Impact factor: 2.370

2.  Potential Role of H-Ferritin in Mitigating Valvular Mineralization.

Authors:  Katalin Éva Sikura; László Potor; Tamás Szerafin; Abolfazl Zarjou; Anupam Agarwal; Paolo Arosio; Maura Poli; Zoltán Hendrik; Gábor Méhes; Melinda Oros; Niké Posta; Lívia Beke; Ibolya Fürtös; György Balla; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

3.  The association of ECG and echocardiographic abnormalities with sudden cardiac death in a dialysis patient cohort.

Authors:  Darren Green; James P Ritchie; Nik Abidin; David I New; Philip A Kalra
Journal:  J Nephrol       Date:  2013-12-12       Impact factor: 3.902

4.  Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification.

Authors:  Cai-Mei Zheng; Kuo-Cheng Lu; Chia-Chao Wu; Yung-Ho Hsu; Yuh-Feng Lin
Journal:  Int J Nephrol       Date:  2011-05-25

Review 5.  QT interval in CKD and haemodialysis patients.

Authors:  Biagio Di Iorio; Antonio Bellasi
Journal:  Clin Kidney J       Date:  2013-01-17

Review 6.  Hydrogen sulfide inhibits aortic valve calcification in heart via regulating RUNX2 by NF-κB, a link between inflammation and mineralization.

Authors:  Katalin Éva Sikura; Zsolt Combi; László Potor; Tamás Szerafin; Zoltán Hendrik; Gábor Méhes; Péter Gergely; Matthew Whiteman; Lívia Beke; Ibolya Fürtös; György Balla; József Balla
Journal:  J Adv Res       Date:  2020-07-21       Impact factor: 10.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.